These findings demonstrate accelerated cerebral atrophy in PCNSL after consolidation compared to healthy adults. However, atrophy did not differ by consolidation strategy. These long-term results suggest acceptable neurotoxicity following RD-WBRT.
Results of major clinical trial may pave the way to health insurance coverage for treatment-resistant cases
Oncogene – Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma
Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential use of GLP-1 or GLP agonist and incretin mimetics during…
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides insight into the 5th iteration of the World Health Organization’s (WHO)…
Chimeric antigen receptor (CAR) T-cell therapy has changed treatment landscape of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and more older patients have…
Introduction: The association of acute lymphoblastic leukaemia (ALL) and cystic fibrosis (CF) is rare. We present the case of a paediatric patient affected by C…
Cancer Discovery | 14 | 11 | November 2024
Peripheral immune cells play an important role in the pathology of Alzheimer’s disease (AD), impacting processes such as amyloid and tau protein aggregation, glial activation,…
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
